drugset / Trial / NCT06212102

Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation

NCT06212102

Phase 2 Recruiting 120 enrolled Bedaya Hospital Cairo University · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

The aim of this randomized controlled trial is to compare the efficacy and cost-effectiveness of using progestin with GnRH antagonist to prevent premature LH surge in poor responders undergoing double stimulation protocol.

Timeline

Start
2024-05-08
Primary completion
2027-03-01
Completion
2027-08-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cetrorelix Other / unclassified 0.2 mg
Subject Dydrogesterone Other / unclassified 30 mg
Background HMG Unknown 300 iu

Indications